New Hope for People With Aggressive Form of Lymphoma [Video]

Key Takeaways

A experimental five-drug combo is significantly improving outcomes for patients with an aggressive cancer of the immune systemSome patients with aggressive B-cell lymphoma achieved full remission, researchers sayStudy participants either had recurrent cancer or were no longer responding to treatment

FRIDAY, June 21, 2024 (HealthDay News) — An experimental cancer treatment regimen is achieving full remissions in some patients with aggressive B-cell lymphoma, researchers report.

The five-drug combination does not include chemotherapy. Rather, it simultaneously zeroes in on several molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors rely on to survive. B-cell lymphoma is a cancer of cells in the body’s immune system. DLBCL is the most common type of lymphoma.

This clinical trial, conducted by researchers from the National Institutes of Health, included 50 patients with DLBCL whose prognosis was grim. Their cancers had either returned after periods of remission or were no longer responding to treatment.

“Many …